Indaptus Therapeutics Stock Gains 8% On Clinical Trial Expansion

(RTTNews) - Indaptus Therapeutics, Inc. (INDP) is trading at $0.8661, up 8.13 percent or $0.0651 during Tuesday's trading, after announcing the expansion of its Phase 1b/2 clinical trial of Decoy20.

The stock opened at $0.9450 and has traded between $0.8500 and $1.7000 so far, compared to a previous close of $0.8010 on the Nasdaq. Trading volume is 15.75 million shares, below the average volume of 23,844. The stock's 52-week range is $0.7010 to $3.1000.

The trial will now evaluate Decoy20 in combination with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, focusing on safety, dose optimization, and early anti-tumor activity.